Chemistry: molecular biology and microbiology – Maintaining blood or sperm in a physiologically active state...
Reexamination Certificate
2009-09-22
2010-12-07
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Maintaining blood or sperm in a physiologically active state...
Reexamination Certificate
active
07846651
ABSTRACT:
A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
REFERENCES:
patent: 6417165 (2002-07-01), Valmori et al.
patent: 6664232 (2003-12-01), Itoh et al.
patent: 2002/0039583 (2002-04-01), Subjeck et al.
patent: 2003/0148463 (2003-08-01), Kufer et al.
patent: 2325345 (1999-10-01), None
patent: 8-500103 (1996-01-01), None
patent: 11-318455 (1999-11-01), None
patent: 2000-116383 (2000-04-01), None
patent: 2001-245675 (2001-09-01), None
patent: 2002-510496 (2002-04-01), None
patent: 2003-270 (2003-01-01), None
patent: 2003-510334 (2003-03-01), None
patent: 2003-533175 (2003-11-01), None
patent: 94/03435 (1994-02-01), None
patent: 97/15597 (1997-05-01), None
patent: 00/06595 (2000-02-01), None
patent: 01/23421 (2001-04-01), None
patent: 01/36453 (2001-05-01), None
patent: 03/012086 (2003-02-01), None
Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains”, J. Immunol., 152:163-175 (1974).
Tajima et al., “Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses”, Tissue Antigens, 64(6):650-659 (2004).
Ullenhag et al., “Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response”, Clin. Cancer Res., 9(7):2447-2456 (2003).
Australian Office Action (Written Opinion) for Application No. SG 200604873-0, dated Oct. 5, 2007.
Australian Search Report for Application No. SG 200604873-0, dated Oct. 5, 2007.
European Communication (Supplementary European Search Report) for EP 05703824, dated Dec. 6, 2007.
Englehard “Structure of Peptides Associated with Class I & II MHC Molecules”, Annual Review of Immunology, pp. 181-207 (1994).
Trojan et al., “Generation of Cytotoxic T Lymphocytes against Native and Altered Peptides of Human Leukocyte Antigen-A*0201 Restricted Epitopes from the Human Epithelial Cell Adhesion Molecule”, Cancer Research, 61:4761-4765 (2001).
Ras et al., “Identification of Potential HLA-A *0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Anitgen (CEA)” American Society for Histocompatibility & Immunogenetics, 53:81-89 (1997).
Aichi Prefecture
Otsuka Pharmaceutical Co. Ltd.
Sughrue & Mion, PLLC
Yu Misook
LandOfFree
Epitope/peptide recognized by HLA-A2402-restricted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epitope/peptide recognized by HLA-A2402-restricted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epitope/peptide recognized by HLA-A2402-restricted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4163528